Bioelectric properties of human cystic fibrosis and non-cystic fibrosis fetal tracheal xenografts in SCID mice

被引:13
|
作者
Tirouvanziam, R
Desternes, M
Saari, A
Puchelle, E
Péault, B
Chinet, T
机构
[1] CNRS, Inst Embryol Cellulaire & Mol, UPR 9064, F-94736 Nogent Sur Marne, France
[2] Univ Paris 05, Lab Biol & Pharmacol Epitheliums Resp, F-92104 Boulogne, France
[3] INSERM, U314, F-51092 Reims, France
来源
关键词
cystic fibrosis transmembrane conductance regulator; airway epithelium; chloride secretion; sodium absorption; fetal airway development;
D O I
10.1152/ajpcell.1998.274.4.C875
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
We measured the bioelectric properties of 14 cystic fibrosis (CF) and 33 non-CF human fetal tracheal xenografts in severe combined immunodeficiency (SCID) mice. All xenografts exhibited a mature airway-type epithelium irrespective of their gestational age, duration of engraftment, and genotype. The in vivo potential difference and the in vitro baseline short-circuit current (I-sc) were significantly higher in non-CF than in CF xenografts. In non-CF xenografts, sequential addition of amiloride, forskolin, and ATP resulted in a 39.4% decrease, a 24.1% increase, and a 43.6% increase in I-sc, respectively. In CF xenografts, forskolin had no significant effect on I-sc, whereas amiloride-and ATP-induced changes in I-sc were proportionally higher than in non-CF xenografts (-60.0 and +68.8%, respectively). These results indicate that the bioelectric properties of non-CF xenografts are similar to those of postnatal airways and that CF xenografts exhibit lower baseline electrogenic activity than non-CF xenografts but similar regulation of ion transport processes to postnatal CF airways. This model of mature human fetal tracheal mucosa may help gain insight into early CF airway pathogenesis.
引用
收藏
页码:C875 / C882
页数:8
相关论文
共 50 条
  • [21] Aspergillus Species in Bronchiectasis: Challenges in the Cystic Fibrosis and Non-cystic Fibrosis Airways
    Chotirmall, Sanjay H.
    Teresa Martin-Gomez, Maria
    MYCOPATHOLOGIA, 2018, 183 (01) : 45 - 59
  • [22] Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis
    Bergin, David A.
    Hurley, Killian
    Mehta, Adwait
    Cox, Stephen
    Ryan, Dorothy
    O'Neill, Shane J.
    Reeves, Emer P.
    McElvaney, Noel G.
    JOURNAL OF INFLAMMATION RESEARCH, 2013, 6 : 1 - 10
  • [23] Management of non-cystic fibrosis bronchiectasis
    Webb, Philip
    King, Jenny
    Baxter, Caroline
    Lord, Robert W.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2021, 82 (07)
  • [24] Update on non-cystic fibrosis bronchiectasis
    Bilton, Diana
    CURRENT OPINION IN PULMONARY MEDICINE, 2008, 14 (06) : 595 - 599
  • [25] Minor role of Cl- secretion in non-cystic fibrosis and cystic fibrosis human nasal epithelium
    Rückes-Nilges, C
    Weber, U
    Lindemann, H
    Münker, G
    Clauss, W
    Weber, WM
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 1999, 9 (01) : 1 - 10
  • [26] Non-cystic fibrosis bronchiectasis in children
    Gursoy, Tugba Ramasli
    Eyuboglu, Tugba Sismanlar
    Aslan, Ayse Tana
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [27] Statins for non-cystic fibrosis bronchiectasis
    Feldman, Charles
    LANCET RESPIRATORY MEDICINE, 2014, 2 (06): : 431 - 432
  • [28] Treatment of Non-Cystic Fibrosis Bronchiectasis
    Martinez Garcia, Miguel Angel
    Maiz Carro, Luis
    Catalan Serra, Pablo
    ARCHIVOS DE BRONCONEUMOLOGIA, 2011, 47 (12): : 599 - 609
  • [29] Cough in non-cystic fibrosis bronchiectasis
    Kantar, Ahmad
    Song, Woo-Jung
    Bush, Andrew
    Chatziparasidis, Grigorios
    ERJ OPEN RESEARCH, 2024, 10 (06)
  • [30] Management of Non-Cystic Fibrosis Bronchiectasis
    Dull, Stacey K.
    Havlat, Brooke D.
    Sanley, Michael J.
    Malesker, Mark A.
    CONSULTANT PHARMACIST, 2018, 33 (11): : 658 - 666